Relevant bibliographies by topics / Anti-cytokines immunotherapy

Academic literature on the topic 'Anti-cytokines immunotherapy'

Author: Grafiati
Published: 11 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Anti-cytokines immunotherapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Anti-cytokines immunotherapy"

1

Tartour, E., R. S. Lee, and W. H. Fridman. "Anti-cytokines: promising tools for diagnosis and immunotherapy." Biomedicine & Pharmacotherapy 48, no. 10 (January 1994): 417–24. http://dx.doi.org/10.1016/0753-3322(94)90002-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

van Montfrans, C., L. Camoglio, and S. J. H. van Deventer. "Immunotherapy of Crohn's disease." Mediators of Inflammation 7, no. 3 (1998): 149–52. http://dx.doi.org/10.1080/09629359891063.

Full text
Abstract:
Although the initiating events of Crohn's disease are unknown, models of experimental colitis have provided new insights in the immunologically mediated pathways of mucosal inflammation. In Crohn's disease activated mucosal T lymphocytes produce proinflammatory cytokines within the mucosal compartment. With this understanding, there has been a shift in past years from the use of unspecific anti-inflammatory agents (corticosteroids, aminosalicylates) to the use of immunomodulatory drugs (azathioprine, methotrexate). Moreover, novel strategies have been designed for specific targets in Crohn's disease, in particular T lymphocytes and cytokines. In an open label study treatment of steroid-refractory Crohn's disease with anti- CD4+ antibodies was well tolerated and showed clinical benefit. However, a sustained depletion of the CD4+ cells precluded further clinical trials. In controlled clinical studies, anti-tumour necrosis factor (TNF-α) antibodies induced com plete remissions and few side effects were observed. One study suggested efficacy in active Crohn's disease of recombinant interleukin-10. Long term treatment studies will have to answer questions about the indications for use, benefit and toxicity. Altogether, these results hold promise for future management of Crohn's disease, where disease-modifying interventions and strategies that effectively maintain disease remission will play a key role.
APA, Harvard, Vancouver, ISO, and other styles
3

Bhushan, Monica, Nicholas M. Craven, and Christopher E. M. Griffiths. "Immunotherapy of Psoriasis." Journal of Cutaneous Medicine and Surgery 1, no. 3 (January 1997): 175–84. http://dx.doi.org/10.1177/120347549700100313.

Full text
Abstract:
Background: Psoriasis is a common inflammatory skin disease, characterized by epidermal keratinocyte hyperproliferation and an inflammatory infiltrate. Current research indicates that epidermal hyperproliferation is, in part, dependent upon the milieu of cytokines and growth factors produced chiefly by T cells within the infiltrate and that the T cells play a central role in the pathogenesis of psoriasis. Objective: Recent developments in the treatment of psoriasis are discussed in the context of current understanding of the pathogenesis of this condition. Conclusion: Significant advances are being made in the treatment directed against these specific immunologic aberrations. Efficacy of immunosuppressive agents such as cyclosporine, FK506 (tacrolimus), anti-CD4 monoclonal antibodies, and IL-2 fusion-toxin in the treatment of psoriasis underscore its probable immune basis. Highly specific treatment directed against cytokines, angiogenesis, and adhesion molecules remains experimental, but shows promise for safer systemic treatment in the future.
APA, Harvard, Vancouver, ISO, and other styles
4

Lee, J. H., S. Y. Lim, A. M. Menzies, M. S. Carlino, A. Guminski, K. Nahar, D. Palmieri, et al. "Pre-treatment circulating cytokines predict toxicity with combination anti-PD1 and anti-CTLA4 immunotherapy." Annals of Oncology 29 (October 2018): viii659. http://dx.doi.org/10.1093/annonc/mdy303.031.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Gordon, Bruce R. "Future Immunotherapy: What Lies Ahead?" Otolaryngology–Head and Neck Surgery 113, no. 5 (November 1995): 603–5. http://dx.doi.org/10.1177/019459989511300512.

Full text
Abstract:
There is currently great interest in developing improved methods of immunotherapy and new techniques of immune system manipulation to ameliorate allergic diseases. This article reviews current research trends in the immunologic treatment of allergy, including the use of chemically modified allergens, nonparenteral allergen exposure, sustained-release allergen delivery, anti-immunoglobulin E antibodies, γ-globulin, immune complexes, cytokines, and T-cell-tolerogenic peptides.
APA, Harvard, Vancouver, ISO, and other styles
6

Bacot, Silvia M., Taylor A. Harper, Rebecca L. Matthews, Christie Jane Fennell, Adovi Akue, Mark A. KuKuruga, Shiowjen Lee, Tao Wang, and Gerald M. Feldman. "Exploring the Potential Use of a PBMC-Based Functional Assay to Identify Predictive Biomarkers for Anti-PD-1 Immunotherapy." International Journal of Molecular Sciences 21, no. 23 (November 27, 2020): 9023. http://dx.doi.org/10.3390/ijms21239023.

Full text
Abstract:
The absence of reliable, robust, and non-invasive biomarkers for anti- Programmed cell death protein 1 (PD-1) immunotherapy is an urgent unmet medical need for the treatment of cancer patients. No predictive biomarkers have been established based on the direct assessment of T cell functions, the primary mechanism of action of anti-PD-1 therapy. In this study, we established a model system to test T cell functions modulated by Nivolumab using anti-CD3 monoclonal antibody (mAb)-stimulated peripheral blood mononuclear cells (PBMCs), and characterized T cell functions primarily based on the knowledge gained from retrospective observations of patients treated with anti-PD-1 immunotherapy. During a comprehensive cytokine profile assessment to identify potential biomarkers, we found that Nivolumab increases expression of T helper type 1 (Th1) associated cytokines such as interferon-γ (IFN-γ) and interleukin-2 (IL-2) in a subset of donors. Furthermore, Nivolumab increases production of Th2, Th9, and Th17 associated cytokines, as well as many proinflammatory cytokines such as IL-6 in a subset of donors. Conversely, Nivolumab treatment has no impact on T cell proliferation, expression of CD25, CD69, or Granzyme B, and only modestly increases in the expansion of regulatory T cells. Our results suggest that assessment of cytokine production using a simple PBMC-based T cell functional assay could be used as a potential predictive marker for anti-PD-1 immunotherapy.
APA, Harvard, Vancouver, ISO, and other styles
7

Terlikowska, K. M., B. Dobrzycka, and SJ Terlikowski. "Ovarian cancer and inflammation. Part 2. Anti-inflammatory cytokines." Progress in Health Sciences 8, no. 2 (December 31, 2018): 206–9. http://dx.doi.org/10.5604/01.3001.0012.8348.

Full text
Abstract:
Inflammation plays a key role in epithelial ovarian cancer tumorigenesis and progression. The growth and progression of epithelial ovarian cancer may be due to local cytokine-induced immunosu-ppression, which may lead to an immunity impairment. Thus, cytokine antagonism may be an essential factor in the treatment of ovarian cancer. Based on the increased knowledge on the role of the immune system in ovarian cancer, major improvements are to be expected of immunotherapy based treatment of this disease. This article aims to summarize the current literature views on the evidence for a role for chronic inflammation with a specific focus on anti-inflammatory cytokines.
APA, Harvard, Vancouver, ISO, and other styles
8

Dimitrov, Dimitre H., Shuko Lee, Jesse Yantis, Craig Honaker, and Nicole Braida. "Cytokine Serum Levels as Potential Biological Markers for the Psychopathology in Schizophrenia." Advances in Psychiatry 2014 (December 11, 2014): 1–7. http://dx.doi.org/10.1155/2014/493505.

Full text
Abstract:
We discuss the role of immune system disturbance in schizophrenia and especially changes of serum levels of cytokines in patients with schizophrenia. The cytokines are essential to wide range of functions related to the defense of the organisms from infectious and environmental dangers. However it is not known whether cytokines influence the presentation of psychotic symptoms. Identification of changes in the serum level of certain cytokines and their correlation with distinct psychopathological symptoms may facilitate the identification of subgroups of patients who are likely to benefit from immunotherapy or anti-inflammatory therapy. Such patients may benefit from tailored immunotherapy designed for modulation of abnormal cytokine levels related to specific positive or negative symptoms of schizophrenia.
APA, Harvard, Vancouver, ISO, and other styles
9

Mirlekar, Bhalchandra, and Yuliya Pylayeva-Gupta. "IL-12 Family Cytokines in Cancer and Immunotherapy." Cancers 13, no. 2 (January 6, 2021): 167. http://dx.doi.org/10.3390/cancers13020167.

Full text
Abstract:
The IL-12 family cytokines are a group of unique heterodimeric cytokines that include IL-12, IL-23, IL-27, IL-35 and, most recently, IL-39. Recent studies have solidified the importance of IL-12 cytokines in shaping innate and adaptive immune responses in cancer and identified multipronged roles for distinct IL-12 family members, ranging from effector to regulatory immune functions. These cytokines could serve as promising candidates for the development of immunomodulatory therapeutic approaches. Overall, IL-12 can be considered an effector cytokine and has been found to engage anti-tumor immunity by activating the effector Th1 response, which is required for the activation of cytotoxic T and NK cells and tumor clearance. IL-23 and IL-27 play dual roles in tumor immunity, as they can both activate effector immune responses and promote tumor growth by favoring immune suppression. IL-35 is a potent regulatory cytokine and plays a largely pro-tumorigenic role by inhibiting effector T cells. In this review, we summarize the recent findings on IL-12 family cytokines in the control of tumor growth with an emphasis primarily on immune regulation. We underscore the clinical implications for the use of these cytokines either in the setting of monotherapy or in combination with other conventional therapies for the more effective treatment of malignancies.
APA, Harvard, Vancouver, ISO, and other styles
10

Chung, Fan. "Anti-inflammatory cytokines in asthma and allergy: interleukin-10, interleukin-12, interferon-γ." Mediators of Inflammation 10, no. 2 (2001): 51–59. http://dx.doi.org/10.1080/09629350120054518.

Full text
Abstract:
Interleukin-10 (IL-10) is a cytokine derived fromCD4+T-helper type 2 (TH2) cells identified as a suppressor of cytokines from T-helper type 1(TH1) cells. Interleukin-12 (IL-12) is produced by B cells, macrophages and dendritic cells, and primarily regulates TH1cell differentiation, while suppressing the expansion of TH2cell clones. Interferon-γ (IFN-γ) is a product of TH1cells and exerts inhibitory effects on TH2cell differentiation. These cytokines have been implicated in the pathogenesis of asthma and allergies. In this context, IL-12 and IFN-γ production in asthma have been found to be decreased, and this may reduce their capacity to inhibit IgE synthesis and allergic inflammation. IL-10 is a potent inhibitor of monocyte/macrophage function, suppressing the production of many pro-inflammatory cytokines. A relative underproduction of IL-10 from alveolar macrophages of atopic asthmatics has been reported. Therapeutic modulation of TH1/TH2imbalance in asthma and allergy by mycobacterial vaccine, specific immunotherapy and cytoline-guanosine dinucleotide motif may lead to increases in IL-12 and IFN-γ production. Stimulation of IL-10 production by antigen-specific T-cells during immunotherapy may lead to anergy through inhibition of CD28-costimulatory molecule signalling by IL-10s anti-inflammatory effect on basophils, mast cells and eosinophils.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Anti-cytokines immunotherapy"

1

Bird-Gordon, Kereen Suzetta. "Prostate Cancer Cells differentally express anti-inflmmatory and pro-inflammatory cytokines and chemokines: implications for prostate cancer immunotherapy." DigitalCommons@Robert W. Woodruff Library, Atlanta University Center, 2007. http://digitalcommons.auctr.edu/dissertations/12.

Full text
Abstract:
Anti-inflammatory specific cytokines and chemokines are elevated in many advanced tumors and correlate with poor prognosis. However, the differential expression of anti-inflammatory cytokines and chemokines in prostate cancer is not known. We investigated the hypotheses that androgen unresponsive DU145 and PC3 prostate cancer cells and androgen responsive LNCaP prostate cancer cells, differentially expressed selected anti-inflammatory and pro-inflammatory cytokines and chemokines and that, dendritic cells pulsed with prostate tumor antigens will induce mainly pro-inflammatory cytokines and chemokines in T cells using mouse models. Our results indicated that anti-inflammatory specific cytokines IL-1 0, IL-4, and anti-inflammatory specific chemokine CCL- 17 (TARC) and cognate receptor CCR4 are expressed in prostate cancer cell lines. Quantitative real-time PCR (qRT-PCR) revealed an almost five-fold increase in chemokine CCL17 and its cognate receptor CCR4 mRNA in androgen unresponsive DU145 and PC3 prostate cancer cell lines compared to androgen responsive prostate tumor LNCaP. Protein analysis indicated significantly increased secretion of anti-inflammatory cytokine IL- 10 by DU145 and PC3 compared to LNCaP. Furthermore, pro-inflammatory cytokine IFN-y and pro-inflammatory chemokine IP- 10 secretion were significantly less in these prostate cancer cells, when compared to immortalized normal prostate epithelial cells. Our in- vivo analysis revealed that T cells were activated by pulsed dendritic cells shown in the increase mRNA expression of pro-inflammatory cytokine IFN-y and pro-inflammatory chemokine IP- 10, and cognate receptor CXCR3. However, a predominant pro-inflammatory response was not observed as anti-inflammatory cytokines and chemokines were also seen. The production of anti-inflammatory cytokines and chemokines suggests a possible mechanism for prostate cancer to evade host immune responses by negatively modulating immune responses that are necessary for destroying cancers cells.. Cytokine and chemokine profiles could be used as potential prognostic markers for disease progression. Additionally, an effacious vaccine will depend on its ability to inhibit the recruitment of known distinct functional anti-inflammatory effector molecules, implicated in prostate cancer progression.
APA, Harvard, Vancouver, ISO, and other styles
2

Gustafsson, Liljefors Maria. "Immunotherapy with the anti-EpCAM monoclonal antibody and cytokines in patients with colorectal cancer : a clinical and experimental study /." Stockholm, 2005. http://diss.kib.ki.se/2005/91-7140-499-6/.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Anti-cytokines immunotherapy"

1

Zemskov, Vladimir, and Veronika Zemskova. Immunotropic effects of therapeutic factors. ru: INFRA-M Academic Publishing LLC., 2020. http://dx.doi.org/10.12737/1039485.

Full text
Abstract:
Data on the immunotropic effects of traditional drugs - antibiotics, antihistamines, anti-inflammatory, and metabolic agents-are summarized. The profile properties of cytostatics, immune globulins, cytokines, vaccines, interferons and their ability to develop General organizational effects are analyzed. Data on the types, blocks, principles of immunotherapy administration, and ways to prevent complications are highlighted. For students and teachers, as well as employees of medical universities.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Anti-cytokines immunotherapy"

1

Garc´ıa-Mart´ınez, K., P. L. Luaces-A´ lvarez, L. Sa´nchez-Valde´s, K. Le´on-Monz´on, T. Crombet-Ramos, and R. P´erez-Rodr´ıguez. "Understanding the Impact of Cuban Immunotherapy Protocols During COVID-19 Disease: Contributions from Mathematical Modeling and Statistical Approaches." In Moving From COVID-19 Mathematical Models to Vaccine Design: Theory, Practice and Experiences, 435–67. BENTHAM SCIENCE PUBLISHERS, 2022. http://dx.doi.org/10.2174/9789815051902122010015.

Full text
Abstract:
<div>Cuban protocols to treat patients with COVID-19 include interferon alpha 2B and</div><div>anti-inflammatory therapy at different moments of the progression of the disease. Here, we</div><div>present the results obtained using a mathematical model to study the immunopathology associated</div><div>with COVID-19. Model simulations reproduce the clinical observations for the antiviral and anti-inflammatory therapies and provide explanations for their efficacy from an immunological</div><div>point of view. In addition, we present new data and statistical analysis of the clinical use of</div><div>itolizumab, a humanized anti-CD6 antibody that reduces the secretion of multiple inflammatory</div><div>cytokines. Authors concluded that the timely use of itolizumab can reduce the probability of death</div><div>while its late prescription might not significantly reduce COVID-19 morbidity and mortality.</div>
APA, Harvard, Vancouver, ISO, and other styles
2

Mukherjee, Saikat, Soubhik Ghosh, and Arindam Bhattacharyya. "Regulation of T-reg/Th-17 Balance: One Step Closer Towards Immunotherapy Against Malaria Infection." In Plasmodium Species and Drug Resistance [Working Title]. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.97045.

Full text
Abstract:
According to World Malaria Report 2020, the rate of decline in malaria case incidence and deaths caused by malaria has ceased in latter half of the past decade. Though Artemisinin Combination Therapy (ACT) is still the major therapeutic approach globally to treat malaria patients, increased resistance of Plasmodium sp. to artemisinin can be looked upon as a major factor responsible for the rate of decline. In the present world, immunotherapeutic approaches are in the limelight to treat several infections, autoimmune disorders, cancers but application of such therapeutic measures in case of malaria are yet not available. Among different immune cells, T-regulatory cells (T-reg) and Th-17 cells and the balance between them, helps in determining the outcome of the immune response in host during both lethal and non-lethal malaria. TGFβ and IL-6 are two major cytokines that play important role in fine tuning the Treg/Th-17 balance by modulating dendritic cell responses, specially by regulating the ratio between myeloid DC and plasmacytoid DC (mDC/pDC). Studies in rodent malaria models have revealed that neutralization of IL-6 by using anti IL-6 monoclonal antibodies in-vivo has been found effective in declining the parasitemia, malaria induced deaths and also in reverting back the altered T-reg/Th-17 balance to normal levels. Apart from these, autophagy is one of the major factors which also contributes to regulate the T-reg/Th-17 balance. In malaria infected mice, autophagy induction has been found to normalise the dysregulated T-reg/Th-17 ratio and promote anti-inflammatory Th-2 pathway by supressing pro-inflammatory Th-1 pathway. So, Treg/Th-17 balance and its associated regulators can be important immunotherapeutic targets for malaria prevention in near future.
APA, Harvard, Vancouver, ISO, and other styles
3

N. Pramod, Siddanakoppalu. "Immunological Basis for the Development of Allergic Diseases-Prevalence, Diagnosis and Treatment Strategies." In Cell Interaction - Molecular and Immunological Basis for Disease Management. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.95804.

Full text
Abstract:
Allergy is an immune disorder due to over responsiveness of immune system to a relatively normal and harmless antigen; derived from environmental and dietary substances commonly referred as allergens. Allergy is an IgE mediated type I hypersensitivity which is characterized by the degranulation of specialized white blood cells known as mast cells and basophils. Majority of characterized allergens are proteinaceous in nature and induce Th2 response. Specific Th2 cytokines elicit the induction of allergen specific IgE antibodies in sensitive individuals. The IgE binds to Fc epsilon receptor on basophil/mast cells and on exposure, allergens cross links the IgE and induce release of hypersensitivity mediators that result in allergic symptoms. The symptoms varies from mild allergies like hay fever, itchiness, rashes, rhinatisis, conjunctivitis to a severe condition such as Asthma and some time life threatening anaphylaxis. At present a various blood based test exist to diagnose allergies which include skin prick, patch test and Specific IgE tests. The best treatment available is to avoid exposure to allergens alternatively use of anti-histamines, steroids or other symptom reducing medications are in practice. Immunotherapy to desensitize the response to allergen and targeted therapy are promising for allergy in future.
APA, Harvard, Vancouver, ISO, and other styles
4

Amedei, Amedeo, and Domenico Prisco. "Cancer Immunotherapy: The Share of Cytokines and Chemokines." In Topics in Anti-Cancer Research, 315–82. BENTHAM SCIENCE PUBLISHERS, 2015. http://dx.doi.org/10.2174/9781681080765115040007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Wooley, Paul H., and Banerjee Subhashis. "Immunotherapy of Collagen-Induced Arthritis with Anti-la and Anti-IL-2R Antibodies." In Monoclonal Antibodies, Cytokines, and Arthritis, 269–88. CRC Press, 2020. http://dx.doi.org/10.1201/9781003066255-13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Anti-cytokines immunotherapy' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography